This interpretation may also shed light on the problem of the “hepsin paradox” [27]: Although hepsin is overexpressed in the vast majority of prostate cancers and is thought to promote tumor progression, it is unexpectedly underexpressed in metastatic lesions. Here, HPN is linked to prostate carcinoma.